Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company’s lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin’s lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
तुलना करने के लिए मीट्रिक्स | ACET | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधACETपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.6x | −2.2x | −0.5x | |
PEG अनुपात | −0.03 | −0.09 | 0.00 | |
क़ीमत/बुक | 0.7x | 1.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 7.0x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 250.8% | 51.2% | |
उचित मूल्य अपसाइड | अनलॉक करें | 19.8% | 7.3% | अनलॉक करें |